The US FDA is finishing guidance explaining a new meeting type for combination product sponsors that will allow pre-submission development agreements – another attempt to smooth the approval process for a sector where historically hurdles often arise.
Agreements are not expected to be binding under the new combination product agreement meeting (CPAM), but could cover a wide variety of issues. John Barlow Weiner, associate director for policy...